Drug information

Co-amilozide

POM

Read time: 19 mins

Last updated: 06 May 2020

Published: 01 Apr 2021

4.1 Therapeutic indications

Co-amilozide is indicated in patients with hypertension, congestive heart failure, or hepatic cirrhosis with ascites, in whom potassium depletion might be anticipated. Amiloride hydrochloride in co-amilozide minimises the possibility of excessive potassium loss during vigorous diuresis for long term therapy. Co-amilozide is particularly indicated in conditions where potassium balance is important, eg patients with congestive heart failure receiving digitalis.

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines

Personalised dashboard providing updates and recommendations for content within your areas of interest

Click here to register now

Learning Zone Homepage

Cardiovascular Metabolism Learning Zone

Type 2 diabetes and hypertension are independent risk factors for the development of cardiovascular disease which are associated with significant increases in morbidity and mortality. However, recent years have seen a substantial advance in both our understanding of the underlying pathophysiology of these conditions, but also in the management of both diseases.

Clinical trial

Confirmatory Clinical Trial of the Evera MRI System for Conditionally-safe MRI Access

The purpose of the Evera MRI™ study is to confirm safety and efficacy of the Evera MRI ICD (Implantable cardioverter-defibrillator)...

1 mins

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).